Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...

Weight-loss medications such as Ozempic, Wegovy, and Mounjaro have attracted widespread attention, making headlines across ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

I t’s hard to overstate just how revolutionary the development of medications like Ozempic and Wegovy has been for managing ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Weight loss medications and bariatric surgery used to be considered last-resort options, but now, they’re everywhere. More ...